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Abstract A six-year-old girl with severe hypercholester-
olemia and atherosclerosis had two defective genes at the 
low-density-lipoprotein (LDL) receptor locus, as deter-
mined by biochemical studies of cultured fibroblasts. One 
gene, inherited from the mother, produced no LDL recep-
tors; the other gene, inherited from the father, produced a 
receptor precursor that was not transported to the cell 
surface and was unable to bind LDL. The patient degraded 
intravenously administered 1251_LDL at an extremely low 
rate, indicating that her high plasma LDL-cholesterollevel 
was caused by defective receptor-mediated removal of 
LDL from plasma. After transplantation of a liver and a 
heart from a normal donor, the patient's plasma LDL-cho-
FAMILIAL hypercholesterolemia is caused by mu-tations in the gene encoding the low-density-lipo-
protein (LDL) receptor. This cell-surface receptor 
normally removes cholesterol-carrying LDL from the 
circulation. l Persons with two mutant LDL-receptor 
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lesterollevel declined by 81 per cent, from 988 to 184 mg 
per deciliter. The fractional catabolic rate for intravenously 
administered 125I-LDL, a measure of functional LDL recep-
tors in vivo, increased by 2.5-fold. Thus, the transplanted 
liver, with its normal complement of LDL receptors, was 
able to remove LDL cholesterol from plasma at a nearly 
normal rate. 
We conclude that a genetically determined deficiency 
of LDL receptors can be largely reversed by liver trans-
plantation. These data underscore the importance of he-
patic LDL receptors in contrOlling the plasma level of LDL 
cholesterol in human beings. (N Engl J Med 1984; 311: 
1658-64.) 
genes (homozygous familial hypercholesterolemia) 
produce few or no LDL receptors and therefore re-
move LDL from plasma at a reduced rate. As a result, 
LDL accumulates in plasma to levels up to eight times 
normal, and total plasma cholesterol levels frequently 
reach 1000 mg per deciliter (30 mmol per liter). These 
patients almost always have severe atherosclerosis in 
childhood, with death from myocardial infarction of-
ten occurring before the age of 20.2 
The heterozygous form offamilial hypercholesterol-
emia, in which a single mutant LDL-receptor gene is 
inherited, occurs at a frequency of 1 in 500 in the 
general population. Affected persons produce on aver-
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age about half the normal number ofLDL receptors. 2 
LDL accumulates to twice the normal level, and 
symptomatic atherosclerosis usually occurs in the 
fourth and fifth decades oflife. Typically, each hetero-
zygote for familial hypercholesterolemia will transmit 
the mutant gene to half of his or her children, who then 
become heterozygotes. \Vhen two heterozygotes marry 
(as occurs in 1 of250,000 marriages), one fourth of the 
o£I5pring will inherit a copy of the mutant LDL-recep-
tor gene from both parents, and these offspring will be 
homozygotes. 
Considerable progress has been made in the under-
standing of familial hypercholesterolemia at the basic 
and clinical levels. The LDL receptor has been puri-
fied, and specific antibodies have been obtained.3 The 
messenger RNA and the gene for the LDL receptor 
have been cloned, and the amino acid sequence of the 
protein has been deduced." The human gene has been 
localized to chromosome 19.5 
Biosynthetic studies have revealed that the LDL 
receptor is synthesized as a glycoprotein precursor 
that has an apparent molecular weight of 120,000.6,7 
Within 30 minutes after synthesis, the receptor is 
transported to the Golgi complex, where its carbohy-
drate chains are elongated. After this processing, the 
migration of the receptor on sodium dodecyl sulfate 
gels is retarded, so that it corresponds to an apparent 
molecular weight of 160,000. A few minutes later the 
receptor appears on the cell surface, where it binds to 
LDL and clusters in coated pits, carrying the bound 
LDL into the cell for degradation. 
At least eight mutant alleles (genes) at the LDL-
receptor locus have been identified in patients with 
familial hypercholesterolemia. 6 ,8,9 The most common 
allele (the so-called null allele) produces no detectable 
receptors. Another allele produces a receptor that is 
synthesized as a 120,000-dalton precursor that cannot 
be transported to the Golgi complex. These mutant 
receptors do not undergo the carbohydrate-processing 
reactions, and hence they do not increase in apparent 
molecular weight. Since they do not reach the cell 
surface, they cannot bind extracellular LDL and 
hence they are nonfunctional. Other alleles produce 
mutant receptors that bind small amounts of LDL. 
Many homozygotes with familial hypercholesterole-
mia have inherited different alleles from each parent, 
and hence they are not true homozygotes but rather 
compound heterozygotes, analogous to patients with 
two mutant ,B-globin genes, as in sickle C disease. 
Treatment of familial hypercholesterolemia in ho-
mozygotes has been unsatisfactory since most of the 
manipulations that lower plasma LDL concentrations 
act by stimulating normal genes in the liver to produce 
more LDL receptors.lO,ll The possibility of an im-
proved treatment has been raised by two recent ad-
vances: the recognition that up to three fourths of the 
total LDL receptors in the body are located in the 
liver, and progress in surgical and immunologic tech-
niques for liver transplantation. The liver manufac-
tures large numbers of LDL receptors because it re-
quires large amounts of cholesterol for secretion into 
bile, for conversion to bile acids, and for the produc-
tion of lipoproteins. l2-l5 For this reason, transplanta-
tion of a normal liver with its normal receptors should 
theoretically lower LDL levels profoundly in homozy-
gotes. l 
On the basis of this rationale, liver transplantation 
was recently performed in a six-year-old girl with ho-
mozygous familial hypercholesterolemia. l6 Two pre-
vious coronary bypass operations and mitral-valve 
replacement (necessitated by papillary-muscle dys-
function) had failed to arrest her progressive coro-
nary-artery disease. Accordingly, she underwent com-
bined liver-heart transplantation. Starzl et al. recently 
described the clinical aspects of this case and reported 
that the liver-heart transplantation led to a marked 
decrease in the patient's plasma cholesterollevel. l6 In 
the current paper, we describe the biochemical defect 
in this patient's cells and report the results of in vivo 
studies designed to determine whether the liver trans-
plantation lowered her plasma LDL level by provid-
ing a new source of LDL receptors. 
METHODS 
Clinical Data 
The six-year-old girl with homozygous familial hypercholesterol-
emia is designated as Patient FH 728. Her clinical history has been 
reported elsewhere. 16 In September 1983 the diagnosis of homozy-
gous familial hypercholesterolemia was established, and she was 
admitted to the General Clinical Research Center at the University 
of Texas Health Science Center at Dallas, where she underwent a 
lipoprotein-turnover study while receiving no medications. Her 
plasma cholesterol level was above 1000 mg per deciliter (30 mmol 
per liter). Shortly thel eafter, she had a myocardial infarction; 
continuing angina required two coronary bypass operations. During 
the second operation her mitral valve was replaced because of pap il-
lary-muscle dysfunction. Angina continued. In February 1984, 
her liver and heart were replaced with a liver and heart from a 
single donor. The transplant operation was performed at the Uni-
versity of Pittsburgh Health Center after approval by the Human 
Rights Institutional Review Board of the Children's Hospital of 
Pittsburgh. lb 
1 Il.J une 1984, the patient was readmitted to the General Clinical 
Research Center in Dallas for a repeat study of 1251_LDL turnover. 
The second study was carried out while she was taking the following 
daily medications: cydosporine, 150 to 200 mg; prednisone, 7.5 mg; 
captopril, 25 mg; and furosemide (Lasix), 40 mg. The two studies of 
lipoprotein turnover were performed under the guidelines of the 
Human Research Committee of the University of Texas Health 
Science Center at Dallas. 
Cultured Cells 
Human fibroblasts were obtained from skin-biopsy specimens 
and grown in monolayer culture at 37°C in a 5 per cent carbon 
dioxide incu bator. Cells from stock cultures were seeded into 60-mm 
Petri dishes according to a standard protocol and cultured for five to 
six days; maximal synthesis ofLDL receptors was induced by incu-
bation in human lipoprotein-deficient serum for 16 to 48 hours be-
fore study, as described elsewhere. 17 
Assays of LDL Metabolism in Fibroblasts 
Human LDL (density, 1.019 to 1.063 g per milliliter) was pre-
pared by ultracentrifugation, and LDL was radiolabeled with 1251 
by the iodine monochloride method. 17 Cells were incubated in mc-
clium containing 10 per cent (vol/vol) lipoprotein-deficient serum 
for 48 hours before assay. We then measured the binding of 1251_ 
LDL to fibroblast monolayers at 4°C; the binding, internalization, 
and degradation of 125I_LDL by monolayers at 37°C; and the incor-
poration of [14C]0Ieate into cholesteryl [14C]estersY 
Incorporation of [35S]Methlonine into LDL Receptors 
After incubation for 16 hours in medium containing 10 per cent 
lipoprotein-deficient serum, cells were switched to methionine-free 
Dulbecco's modified Eagle medium containing 10 per cent lipopro-
tein-deficient serum. [35S]Methionine (100 /A-Ci per milliliter [100 to 
ISO Ci per millimole]) was added for various times as indicated in 
the figure legends (pulse). The radioactive medium was then re-
moved, and the cells were incubated in complete Dulbecco's modi-
fied Eagle medium (final methionine concentration, 0.1 mM) for the 
indicated times (chase). The monolayers were washed and lysed, 
and LDL receptors were precipitated by incubation with immune 
complexes containing either antireceptor monoclonal antibody IgG-
C7 or a control monoclonal antibody, IgG-2001, as described by 
Tolleshaug et a1.6 The washed immunoprecipitates were dissolved 
in 8 M urea and 0.2 M dithiothreitol and subjected to electrophore-
sis in sodium dodecyl sulfate polyacrylamide gels, followed by Huo-
rography for four days.6 Gels were calibrated with molecular-weight 
standards ranging from 68,000 to 200,000.6 
Lipoprotein-Turnover Studies 
Studies oflipoprotein turnover were carried out as described else-
where. 18 Patient FH 728 was given a partial solid-food diet with a 
caloric distribution of 40 per cent fat (polyunsaturated to saturated 
ratio of 0.33), 40 per cent carbohydrate, and 20 per cent protein. 
The cholesterol intake was limited to 250 mg per day. Each study 
was initiated by intravenous injection of2 ml ofa mixture of 14/A-Ci 
of autologous '25I_LDL, unlabeled native LDL (2 mg), and human 
serum albumin (ISO mg). Kinetic indexes for the disappearance of 
LDL were calculated by the two-pool model ofMatthewsl9 with the 
SAAM computer program.20 
REsULTS 
Fibroblasts from the patient bound, internalized, 
and degraded less than 5 per cent of the normal 
amount of 125I_LDL (Table 1, Experiment A). Fibro-
blasts from the normal donor of the liver and heart 
bound, internalized, and degraded a normal amount 
of 125I_LDL (Table 1, Experiment B). Similar results 
were obtained when we measured the amount of cell-
surface binding at 4°C (data not shown). 
A functional test ofLDL uptake through the recep-
tor mechanism is the stimulation of cholesteryl-ester 
formation. 21 Fibroblasts grown in the absence ofLDL 
have no excess sterols and hence fail to incorporate 
[14C]oleate into cholesteryl [14C]oleate. When the 
cells are incubated with LDL, the incorporation of 
[ 14C]oleate into cholesteryl esters is enhanced. Esteri-
fication can also be stimulated by incubating the cells 
with 25-hydroxycholesterol, which enters cells and 
stimulates cholesteryl-ester synthesis without a re-
quirement for the LDL receptor. To estimate LDL-
receptor function, we compared the stimulation of 
cholesteryl-ester synthesis produced by 25-hydroxy-
cholesterol with the stimulation produced by LDL.21 
As shown in Table 2, normal cells had a 3. I-fold high-
er rate of cholesterol esterification when incubated 
with LDL than when incubated with 25-hydroxycho-
lesterol. In the patient's cells, 25-hydroxycholesterol 
had a normal stimulatory effect, but LDL was com-
pletely ineffective. 
Table 1. Metabolism of 1251_LDL by Fibroblasts from the Patient 



























"Each monolayer was treated with 2 mI of medium containing 5 per cent lipoprotein-
deficient serum and 10 p.g of protein per milliliter of I25I_LDL (140 to 180 cpm per nanogram of 
protein) in the absence or presence of 500 p.g of protein per milliliter of unlabeled LDL. After 
incubation for five hours at 37"C, the total amounts of sorface-hound, internalized, and degrad-
ed I25I_LDL were determined. The data represent high-affinity values, which were determined 
by subtracting the values for 125I_LDL in the presence of unlabeled LDL (nonspecific values) 
from the values in its absence (total values). The nonspecific values comprised <10 per cent of 
the total values. Each value represents the mean of triplicate incubations. 
Both parents of Patient FH 728 had elevated LDL-
cholesterol levels (>95th percentile), as expected in 
heterozygotes for familial hypercholesterolemia. The 
values for total and LDL cholesterol in the mother, 
age 26 years, were 227 and 172 mg per deciliter (5.87 
and 4.45 mmol per liter); the corresponding values in 
the father, age 36 years, were 324 and 253 mg per 
deciliter (8.38 and 6.54 mmol per liter). In fibroblasts 
from both parents, LDL was about half as effective as 
it was in the normal subject in stimulating cholesterol 
esterification (Table 2). The relative rates of esterifica-
tion in these two obligate heterozygotes were within 
the range previously observed for other heterozy-
gotes,2l indicating that both parents produced about 
half the normal number offunctional LDL receptors. 
A similar reduction in LDL-receptor activity was not-
ed when the binding, internalization, and degradation 
of 125I_LDL were measured in fibroblasts (data not 
shown). 
To study the structural basis of the receptor defect 
in the patient's fibroblasts, we incubated the cells for 
one hour with [35S]methionine and then incubated 
them with unlabeled methionine for 15 minutes or two 
hours, after which we solubilized the cells in deter-
gents and immunoprecipitated the LDL receptors 
(Fig. 1). In the normal cells after the 15-minute chase 
period, about half the receptors were in the precursor 
form (120,000 daltons), and half were in the mature 
form (160,000 daltons) (Fig. 1, Lane A). After another 
two-hour incubation, all the receptors had undergone 
processing and were in the mature form (Lane B). The 
patient's cells synthesized a relatively small number of 
immunoprecipitable LDL receptors (Lane C). Even 
after two hours of incubation with unlabeled methio-
nine, these receptors remained in the unprocessed pre-
cursor form (Lane D). Thus, the patient's fibroblasts 
contained at least one copy of the mutant allele that 
produces an abnormal precursor that is not transport-
ed to the Golgi apparatus for carbohydrate processing. 
To identifY the origin of this mutant allele, we per-
formed pulse-chase experiments in cells from both 
Table 2. Incorporation of [14C]Oleate into Cholesteryl Esters by 
Fibroblasts from the Patient and Her Heterozygous Parents.* 
CHOLF.STERYL rI4C]OLEATE FORMED 
PLUS 5 J.Lglrnl OF iai:OR~evaoluv-
NO 200 jLg/ml 25-HYDROXY- CHOLESTEROl 
SL"BJErr ADDITIONS OF LDL CHOLESTEROL RATIO 
(a) (b) (e) (b - a)/(e - a) 
pmol/ill per/mg of protein 
Experiment A 
Normal 198 8800 3000 3.1 
Patient 45 33 2610 0.0 
Experiment B 
Normal 65 5793 2008 2.9 
Patient's mother 40 3841 2950 1.3 
Experiment C 
Normal 235 5210 2330 2.4 
Patient's father 28 1126 916 l.2 
*Each monolayer was treated with 2 ml of medium containing 5 per cent lipoprotein-
deficient serum supplemented with nothing. LDL, or 25-hydroxycholesterol as indicated. After 
incubation for five hours at 37°C. each monolayer was incubated for two hours with 0.1 mM 
rl4Cjoleate-albumin (9580 to 11,820 dpm per nanomole), after which the cells were harvested 
for measurement of cholesteroll l4C]oleate content. Each value represents the mean of triplicate 
incubations. 
parents. As shown in Figure 2, all the receptors pro-
duced by the mother's cells were in the mature form, 
indicating that they were all produced by her single 
normal receptor gene. The father's cells exhibited two 
populations of LDL receptors after a two-hour chasc 
period - one population of normal mature receptors 
and a second population of abnormal precursor recep-
tors that were not processed. All the receptors pro-
duced by the patient's cells remained in the nonproc-
essed precursor form. These data suggested that the 
mother had one copy of a normal allele and one copy 
of a null allele that did not produce immunoprecipita-
ble LDL receptors. The father had one copy of the 
normal allele and one copy of the mutant allele that 
produced a nonprocessed receptor. The patient had 
inherited the null allele from the mother and the allele 
that produced nonprocessed receptors from the father. 
Before transplantation of the liver and heart, the 
patient was given a tracer dose of 1251_LDL intrave-
nously, and blood samples were collected thereafter 
for measurement of radioactivity (Fig. 3). The 1251_ 
LDL left her circulation extremely slowly; after 10 
days, 30 per cent of the injected 125I-LDL remained. 
(In normal subjects, less than 5 per cent of radio-
activity remains in the plasma at this time. 2,22) After 
transplantation, when the patient had been fully am-
bulatory for several months, the study of 125I_LDL 
turnover was repeated. At that time the 125I_LDL was 
removed much more rapidly from the circulation; 
after 10 days, only 5 per cent of the 125I_LDL re-
mained in the plasma. 
The turnover data in Figure 3 were analyzed by the 
two-pool model of Matthews, 19,22 and the indexes are 
shown in Table 3. After transplantation, the patient 
had a decline in the level of total plasma cholesterol, 
from 1079 to 302 mg per deciliter (27.9 to 7.81 mmol 
per liter). Her plasma LDL-cholesterol concentration 
declined from 988 to 184 mg per deciliter (25.5 to 4.76 
mmol per liter). The fractional catabolic rate for plas-
ma 1251-LDL is an accurate index offunctional LDL-
receptor activity in vivo. II - 14 Before transplantation, 
the patient's fractional catabolic rate was 0.12 pools 
per day, which is equal to that attributable to clear-
ance of LDL by nonreceptor pathways I 1,18; in other 
words, there was no detectable expression of the recep-
tor pathway in vivo. After transplantation, the frac-
tional catabolic rate increased to 0.31 pools per day. 
The normal value (mean ±S.D.) for 16 young adults 
was 0.43±0.06 pools per day.11 
On the basis of the measured rate of catabolism of 
1251_LDL and the measured pool size of LDL, the 
production rate ofLDL apoprotein (apo-LDL) can be 
estimated. Although these calculations have limita-
tions,23 they suggest that before transplantation the 
patient produced 36 mg of apo-LDL per kilogram of 
body weight per day, which is four times higher than 
normal (Table 3). After transplantation the calculated 
apo-LDL production rate declined to 16.7 mg per kilo-
gram per day, which is still above normal. The normal 
value (mean ±S.D.) for 16 young adults was 8.5± 1.4 
mg per kilogram per day. II 
DISCUSSION 
The data in this paper demonstrate that our patient 
with the clinical syndrome of homozygous familial hy-












E F G H 
Control 
IgG 
Figure 1. Kinetics of Processing of LDL Receptors in Fibroblasts 
from a Normal Subject and Patient FH 728. 
Cells were incubated in methionine-free medium containing 
[35S1methionine for one hour. The medium was then switched to 
complete medium containing unlabeled methionine for either 15 
minutes (A, C, E, and G) or two hours (8, 0, F, and H), after which 
the cells were dissolved in detergents and LDL receptors were 
immunoprecipitated with monoclonal anti receptor IgG-C7 (A to 
D). Control preCipitations were performed with control monoclonal 
IgG-2001 (E to H). The immunoprecipitates were subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and 
fluorography. The positions of migration of the unprocessed pre-
cursor receptor (120,000 daltons) and the processed mature re-
ceptor (160,000 daltons) are indicated. 
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Figure 2. Electrophoresis of 35S-Labeled LDL Receptors from 
Patient FH 728 and Her Heterozygous Parents. 
Fibroblasts from the indicated subject were incubated in methio-
nine-free medium containing [35Sjmethionine for two hours 
(pulse). The medium was then switched to complete medium for 
two hours (chase), after which LDL receptors were immuno-
precipitated and processed for sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and fluorography. The positions 
of migration of the unprocessed precursor receptor (120,000 
daltons) and the processed mature receptor (160,000 daltons) 
are indicated. 
disorder. From her mother, she inherited a null allele 
that failed to produce immunologically or functionally 
active LDL receptors. From her father, she inherited 
an allele that produced a mutant receptor that could 
not be processed to the mature form and thus could 
not be brought to the cell surface, even though it was 
capable of recognition by a monoclonal antibody di-
rected against the receptor. 
Because of the grim clinical outlook for this patient, 
she underwent a combined heart-liver transplanta-
tion. 16 The liver transplantation was designed to pro-
vide her with an organ that produced normal LDL 
receptors, in the hope that the new receptors would 
remove LDL from the circulation with normal effi-
ciency. The heart transplantation was necessitated 
because of the severe myocardial and valvular dam-
age and because the presence of an artificial valve 
would have been a contraindication to immunosup-
pressive therapy after liver transplantation. 16 The pa-
tient tolerated these operations remarkably well, and 
her postoperative course has been uneventful up to the 
present. 
After transplantation, the plasma LDL-cholesterol 
level in Patient FH 728 declined by 81 per cent. Stud-
ies of 1251_LDL catabolism indicated that the fraction-
al catabolic rate for LDL increased by 2.5-fold, reach-
ing about 67 per cent of the normal value. This finding 
is consistent with the observation in animals that the 
liver accounts for about 75 per cent of the total expres-
sion of LDL receptors in vivo. 12-!5 Presumably, the 
LDL level in our patient would be reduced even fur-
ther if LDL receptors on extrahepatic tissues could be 
restored. Although the transplanted heart also had 
normal LDL receptors, the contribution of this organ 
to removal of LDL from plasma is negligible. 12-14 
In agreement with previous studies in homozy-
gous familial hypercholesterolemia,18,22,24 the appar-
ent rate of LDL production in our patient was in-
creased markedly before transplantation. This finding 
can be explained, at least partly, by a lack of receptor-
mediated uptake of intermediate-density lipoproteins 
in the liver, as determined from studies of \Vatanabe 
heritable hyperlipidemic (WHHL) rabbits, an ani-
mal counterpart of familial hypercholesterolemia.! 
Intermediate-density lipoproteins are derived from 
very-low-density lipoproteins during the transport of 
triglycerides in plasma. Normally, about half the in-
termediate-density lipoproteins are removed from the 
circulation by binding to LDL receptors in the liver. 
In homozygous familial hypercholesterolemia, the in-
termediate-density lipoproteins cannot enter the liver 
normally, owing to the deficiency of LDL receptors. 
As a result, these lipoproteins remain in plasma, 
where thev are eventuallv converted to LDL, thus con-
tributing to overproduction of LDL. 1,23 
The elevated rate ofLDL production in our patient 
was decreased after transplantation, suggesting that 
the new liver was removing intermediate-density lipo-
proteins from the circulation at an accelerated rate. 
However, the precise magnitude of LDL production 
cannot be estimated accurately from our kinetic stud-
ies because the calculations assume that plasma LDL 
is a homogeneous pool and that all of it is catabolized 
at the same rate as the 1251_LDL that was injected. 
Since this assumption is probably not correct,23 the 
calculations for the LDL production rate in Table 3 
should be interpreted with some caution. Neverthe-
o 
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Figure 3. Plasma Decay Curves after Intravenous Injection of 1251_ 
LDL in the Patient before and after Liver-Heart Transplantation. 
Table 3. Clinical Data and Kinetic Indexes for LDL-Turnover Stud-
ies in the Patient before and after Liver-Heart Transplantation. 
125I_LDL TURNOVER STUDY 
BEFORE AFTER 
INDEX TRANSPLANTATION TRANSPLANTATION 
Weight (kg) 20.4 21.1 
Height (em) 112 114 
Plasma cholesterol (mg/dl) * 
Total 1079±31 302±32 
LDL 988± 14 184±23 
HDL 35±3 41±2 
Plasma triglyceride (mg/dl) • 238±76 218±47 
Plasma volume (mI) t 919 955 
Plasma LDL protein (mg/dl) * 673 119 
Half-time for exponential decay (days) :I: 
I st exponential 0.60 0.75 
2nd exponential 7.52 3.15 
FCR (pools/day) § 0.12 0.31 
Apo-LDL production and catabolism 
mg/day 743 353 
mg/kg/day 36.4 16.7 
Apo-LDL distribution ~ 77% 76% 
*Mean of six ~eparate measurements made during the course of each turnover study. Plus-
minus values are S.D. To convert values for cholesterol and triglyceride to millimoles per liter, 
multiply by 0.02586 and 0.01129. respectively. 
tEstimated as 4.5 per cent of body weight. 
:l:Half-times of the first and ~econd exponentials of the plasma decay curve. 
§Fraction of the intravascular apo-LDL pool catabolized each day, calculated from the two 
exponentials of the plasma decay curve. 
~mercentage of total body apo-LDL contained in the intravascular space. 
less, the fall in the apparent production rate, as calcu-
lated from the above model, is consistent with the no-
tion that the transplanted hepatic LDL receptors have 
an important role in regulating the input of LDL as 
well as in promoting its removal. I 
We considered the possibility that the enhanced ca-
tabolism of LDL seen postoperatively in Patient FH 
728 was not due to the functioning of the normal liver 
but to some unanticipated effect of the operation or of 
the postoperative drug regimen. Against this thesis is 
the observation that in seven other patients (ages, 2 to 
12) who underwent liver transplantation for a variety 
of reasons other than familial hypercholesterolemia 
and who were maintained on a similar drug regimen of 
prednisone and cyclosporine, the plasma cholesterol 
level postoperatively was not lowered below normal. 
The mean total cholesterol level in these seven pa-
tients after liver transplantation was 190 mg per decili-
ter (4.9 mmol per liter), the mean LDL-cholesterol 
level was 123 mg per deciliter (3.18 mmol per liter), 
and the mean triglyceride level was 353 mg per decili-
ter (3.99 mmol per liter). 
Although liver transplantation as a method of low-
ering cholesterol is applicable only to the rare patients 
with receptor-negative homozygous familial hyper-
cholesterolemia, less drastic treatments that increase 
the amount of hepatic LDL receptors may have more 
widespread use in the more common types of hy-
percholesterolemia. 25 Patients who have one or two 
copies of the normal LDL-receptor gene can respond 
to agents that stimulate the normal gene to produce 
more LDL receptors. 10,1 1.25 These agents include bile 
acid-binding resins, such as cholestyramine, and oper-
ations, such as ileal bypass, that stimulate the produc-
tion of LDL receptors by enhancing the liver's de-
mand for cholesterol. 26,27 Newer agents, such as the 
cholesterol-synthesis inhibitors compactin and me-
vinolin, also stimulate the production of LDL recep-
tors by inhibiting the liver's cholesterol synthesis and 
forcing the organ to rely on LDL receptors for an in-
creased proportion of its cholesterol supply. I 1.27 These 
treatments will lower LDL-cholesterol levels in pa-
tients with heterozygous familial hypercholesterole-
mia and in patients with two normal receptor genes 
whose receptor production has been suppressed by 
diet and other environmental factors. 
Some homozygotes with familial hypercholesterole-
mia have an incomplete defect and express 5 to 25 per 
cent of the normal amount of LDL-receptor activity.2 
These patients retain a limited potential to respond to 
receptor-enhancing agents. 2 However, receptor-nega-
tive homozygotes, such as Patient FH 728, who lack 
the genetic information to produce any functional 
LDL receptors, cannot respond to these treatments. 2 
The only effective therapies for this latter group are 
the performance of biweekly plasmaphereses28 and 
the performance of a portacaval shunt. 18,29 The lat-
ter operation reduces LDL levels by up to 50 per 
cent by diminishing the rate of production of LDL. 18 
Liver transplantation should be considered only for 
the group of homozygotes with familial hypercholes-
terolemia who are unable to produce any functional 
LDL receptors and do not respond to other forms of 
therapy. 
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medical and surgical care of the patient in Dallas; and to the nursing 
and nutrition staff of the General Clinical Research Center in Dallas 
for devoted assistance during the performance of the metabolic stud-
ies. The University of Pittsburgh transplantation surgeons who op-
erated on and cared for the patient included Henry T. Bahnson, 
Byers W. Shaw, Jr., Robert L. Hardesty, Bartley G. Griffith, and 
Shunzaburo I watsuki. The Pittsburgh pediatric team included Drs. 
Carlton Gartner, Jr., Basil Zitelli, J. Jeffrey Malatack, and Andrew 
Urbach. 
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